Bringing the Oncology Community Together

ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma

Silas Inman
Published Online: Wednesday, December 7, 2011
axitinib molecular structureThe Oncology Drugs Advisory Committee (ODAC) unanimously voted to recommend the approval of axitinib (Inlyta), a tyrosine kinase inhibitor, for the second-line treatment of patients with advanced renal cell carcinoma (RCC).

The recommendation was based on the AXIS 1032 trial, a randomized, open-label, controlled, phase III multicenter study of 723 patients with advanced RCC. Patients were randomized to receive axitinib or sorafenib, both vascular endothelial growth factor (VEGF) inhibitors, with a primary endpoint of progression-free survival (PFS).

The median PFS for the axitinib arm of the trial was 6.7 months compared to 4.7 months in the sorafenib arm. (HR=0.67; 95% CI, 0.55-0.81). Adverse events were not out of the ordinary compared to other VEGF inhibitors. The most common adverse events included diarrhea, nausea, fatigue, asthenia, hypertension, and dermatologic events.

"We are pleased with the panel’s recommendation in support of axitinib for the treatment of previously treated advanced RCC, as additional therapeutic options are still needed for this patient population,” said Dr. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs, Pfizer Oncology Business Unit. “We look forward to continued discussions with the FDA as we take the next steps in the regulatory process for axitinib."

Exclusive Interview With Dr. Brian I. Rini Discussing the AXIS TrialBrian Rini

The FDA sought advice from the panel because of concerns regarding the origin of the PFS benefit demonstrated in the AXIS trial and to decide if the benefits of the drug outweighed the risks. The unanimous vote from the ODAC committee clears axitinib of these concerns.

There are currently 4 other VEGF inhibitors available for RCC, along with 2 drugs that inhibit mammalian target of rapamycin (mTOR).

Kidney cancer is the seventh most common form of cancer among men and the ninth among women in the United States. RCC is responsible for 85% of all cases of kidney cancer.

Related Articles
Pre-Chemo Enzalutamide OS Benefit in mCRPC Reaches Nearly 30%
The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%
One in Five Cancer Trials End Too Early, but GU Studies Not More Likely
The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers.
AXIS Trial: Second-Line Axitinib Versus Sorafenib
In this segment, panelists discuss the AXIS trial and the efficacy of axitinib as a second-line treatment for metastatic renal cell carcinoma.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.